Detalles de la búsqueda
1.
Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry).
J Eur Acad Dermatol Venereol
; 36(11): 2076-2086, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35748102
2.
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
J Eur Acad Dermatol Venereol
; 34(1): 112-118, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31287604
3.
Multi-treatment resistance to biological treatment in patients with psoriasis: Definitions and implications.
J Eur Acad Dermatol Venereol
; 2024 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38818854
4.
The lifestyle of psoriasis patients and their motivation to change.
J Eur Acad Dermatol Venereol
; 2024 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38400656
5.
Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry.
J Eur Acad Dermatol Venereol
; 33(10): 1913-1920, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31177583
6.
Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE.
Br J Dermatol
; 178(5): 1181-1189, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29247500
7.
A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis.
Br J Dermatol
; 178(1): 86-94, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28646581
8.
The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry.
J Eur Acad Dermatol Venereol
; 32(4): 615-623, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29121430
9.
Exclusion by age, cardiovascular comorbidity and malignancies are the main factors that impact generalizability of evidence from trials to the real-world situation in older adults with psoriasis.
J Eur Acad Dermatol Venereol
; 37(12): e1471-e1474, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37471529
10.
Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.
Br J Dermatol
; 177(2): 489-496, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28207934
11.
Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE.
Br J Dermatol
; 177(2): 497-504, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28078672
12.
Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
Br J Dermatol
; 176(5): 1288-1296, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27564082
13.
Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
Br J Dermatol
; 176(4): 1001-1009, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27579864
14.
Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort.
Br J Dermatol
; 176(3): 786-793, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27454758
15.
Data-driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine.
Br J Dermatol
; 185(4): 698-699, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34337747
16.
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
Br J Dermatol
; 175(2): 340-7, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26989852
17.
Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis.
Br J Dermatol
; 172(6): 1621-1627, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25683671
18.
Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry.
J Eur Acad Dermatol Venereol
; 29(3): 560-5, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25088451
19.
An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors.
J Eur Acad Dermatol Venereol
; 29(4): 752-60, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25229823
20.
Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria.
Allergy
; 74(6): 1185-1187, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30593687